Responses to oral Δ9-tetrahydrocannabinol in frequent and infrequent marijuana users

被引:56
|
作者
Kirk, JM [1 ]
de Wit, H [1 ]
机构
[1] Univ Chicago, Dept Psychiat MC3077, Chicago, IL 60637 USA
关键词
oral Delta(9)-THC; marijuana; drug use history; subjective effects;
D O I
10.1016/S0091-3057(98)00264-0
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
It is known that an individual's drug use history affects the quality of subjective effects experienced following administration of several clinically used psychoactive drugs such as barbiturates, diazepam, and morphine. However, it is not known whether drug use history also affects responses to therapeutic cannabinoids such as Delta(9)-THC. Tnt current experiment compared the subjective and behavioral effects of oral Delta(9)-THC in two groups of volunteers: frequent users (FREQ; ii = 11), who reported using marijuana at least 100 times, and infrequent users (INF: n = 10) who reported using marijuana 10 or fewer times. Subjects participated in three sessions during which they received Delta(9)-THC (7.5 and 15 mg) and placebo. They completed subjective effects questionnaires for 5 h following administration. In the FREQ group, the lower dose (7.5 mg) increased ratings of "feel drug," relative to placebo, whereas it had no effect in the INF group. In contrast, at the higher dose (15 mg), ratings of "feel drug" were lower in the FREQ group than in the INF group, suggestive of tolerance. In addition, the INF group reported greater sedative effects than the FREQ group following the higher dose of Delta(9)-THC, again suggesting tolerance to Delta(9)-THC's sedative effects. These findings demonstrate that marijuana use history may affect the subjective effects of oral Delta(9)-THC, but that the influence of drug use history depends on the dose of drug administered. These findings may have implications for the clinical use of Delta(9)-THC and other cannabinoids. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:137 / 142
页数:6
相关论文
共 50 条
  • [21] Urinary pharmacokinetics of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol after controlled oral Δ9-tetrahydrocannabinol administration
    Gustafson, RA
    Kim, I
    Stout, PR
    Klette, KL
    George, MP
    Moolchan, ET
    Levine, B
    Huestis, MA
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2004, 28 (03) : 160 - 167
  • [22] The safety of modafinil in combination with oral Δ9-tetrahydrocannabinol in humans
    Sugarman, Dawn E.
    Poling, James
    Sofuoglu, Mehmet
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2011, 98 (01) : 94 - 100
  • [23] Pharmacokinetic properties of Δ9-tetrahydrocannabinol in serum and oral fluid
    Kauert, Gerold F.
    Ramaekers, Johannes G.
    Schneider, Erhard
    Moeller, Manfred R.
    Toennes, Stefan W.
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2007, 31 (05) : 288 - 293
  • [24] Driving Under the Influence of Marijuana Versus Driving and Dying Under the Influence of Marijuana: A Comparison of Blood Concentrations of Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol, 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol and Other Cannabinoids in Arrested Drivers Versus Deceased Drivers
    Lemos, Nikolas P.
    Nicolas, Alexander C. San
    Volk, Justin A.
    Ingle, Eric A.
    Williams, Chinyere M.
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2015, 39 (08) : 588 - 601
  • [25] Separate and combined effects of gabapentin and 9-tetrahydrocannabinol in humans discriminating 9-tetrahydrocannabinol
    Lile, Joshua A.
    Wesley, Michael J.
    Kelly, Thomas H.
    Hays, Lon R.
    [J]. BEHAVIOURAL PHARMACOLOGY, 2016, 27 (2-3): : 215 - 224
  • [26] Temporal indication of marijuana use can be estimated from plasma and urine concentrations of Δ9-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, and 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid
    Manno, JE
    Manno, BR
    Kemp, PM
    Alford, DD
    Abukhalaf, IK
    McWilliams, ME
    Hagaman, FN
    Fitzgerald, MJ
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2001, 25 (07) : 538 - 549
  • [27] Lack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain
    Buggy, DJ
    Toogood, L
    Maric, S
    Sharpe, P
    Lambert, DG
    Rowbotham, DJ
    [J]. PAIN, 2003, 106 (1-2) : 169 - 172
  • [28] Urinary Excretion Profile of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users
    Spindle, Tory R.
    Cone, Edward J.
    Schlienz, Nicolas J.
    Mitchell, John M.
    Bigelow, George E.
    Flegel, Ronald
    Hayes, Eugene
    Vandrey, Ryan
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2020, 44 (01) : 1 - 14
  • [29] Detection of Δ9-Tetrahydrocannabinol in Exhaled Breath Collected from Cannabis Users
    Beck, Olof
    Sandqvist, Soren
    Dubbelboer, Ilse
    Franck, Johan
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2011, 35 (08) : 541 - 544
  • [30] Influence of Ethanol on the Pharmacokinetic Properties of 9-Tetrahydrocannabinol in Oral Fluid
    Toennes, Stefan W.
    Schneider, Kirsten
    Wunder, Cora
    Kauert, Gerold F.
    Moeller, Manfred R.
    Theunissen, Eef L.
    Ramaekers, Johannes G.
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2013, 37 (03) : 152 - 158